article thumbnail

Opinion: STAT+: Four leading biopharma executives weigh the 2024 election

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. Read

article thumbnail

ACG unveils ADAPT X at CPhI & PMEC India 2024

Express Pharma

ACG Engineering, a division of ACG specialising in manufacturing solutions for the global pharmaceutical and nutraceutical industries, introduced its new ADAPT X feeder at CPhI & PMEC India 2024 in Delhi. Launching ADAPT X at PMEC 2024 allows us to demonstrate the transformative impact of this feeder to industry leaders,” he added.

Packaging 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: STAT+: What the Sandoz CEO is thinking about the 2024 elections

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. 

article thumbnail

STAT+: Eli Lilly raises earnings guidance as Zepbound sales beat expectations

STAT

Eli Lilly raised its full-year guidance on Tuesday while it reported strong first-quarter sales of Zepbound, even as the pharmaceutical company struggles to make enough of the obesity drug to meet the enormous demand. Lilly increased its adjusted earnings guidance for 2024 to a range of $13.50 per share, beating the $2.39

article thumbnail

Opinion: Insulin is increasingly affordable in the U.S. What about the rest of the world?

STAT

Following two decades of sharp increases for consumers, the companies vowed to cut insulin prices for some insulins by at least 70%, meaning many people could see their insulin costs capped at $35 a month in the near future. Sanofi and NovoNordisk will lower their prices as of January 2024; Lilly reduced it to $35 per month in March 2023.)

article thumbnail

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

article thumbnail

Opinion: STAT+: Eli Lilly chief scientist Daniel M. Skovronsky: Beware elected leaders who would weaken patents

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You